Gamida Cell Ltd

-0.07 (-3.11%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)230.18M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.17 Million
Adjusted EPS-$0.20
See more estimates
10-Day MA$2.18
50-Day MA$1.63
200-Day MA$1.68
See more pivots

Gamida Cell Ltd Stock, NASDAQ:GMDA

116 Huntington Avenue, Givaat Shaul, Boston, Massachusetts 02116
Phone: +1.713.400.6400
Number of Employees: 146


Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.